Skip to main content
. 2023 Sep 26;14(9):636. doi: 10.1038/s41419-023-06053-y

Fig. 3. Efficacy of immunotherapy in small cell lung cancer (SCLC) cell lines.

Fig. 3

A mRNA expression levels of YAP1 in different SCLC cell lines. B Protein expression level of YAP1 in different SCLC cell lines. Scale bars indicate median fluorescence intensity. C Cell viability of SCLC by Cell Counting Kits-8 (CCK8) assay in the control group (equivalent volume of PBS), the EC group (etoposide plus cisplatin), the EC/Atezolizumab group (atezolizumab plus etoposide and cisplatin), and the Atezolizumab group. D Gating strategy of early and late apoptotic-tumor cells after drug exposure. E The proportions of early and late apoptotic-tumor cells in different groups. EC etoposide plus cisplatin, FVD Fixable Viability Dye, ns not significant, E/T cells effector and target cells, YAP1 yes-associated protein 1; *p < 0.05.